The aspects of the present disclosure relates to novel lanosterol derivatives and novel 25-hydroxycholesterol derivatives including their pharmaceutically acceptable salts as well as methods of treatment and pharmaceutical compositions and formulations of lanosterol and derivatives thereof and 25-hydroxycholesterol and derivatives thereof useful in treating ophthalmic disorders including cataracts and presbyopia.
本公开涉及的方面涉及新型鲎
甾醇衍
生物和新型25-羟基
胆固醇衍
生物,包括它们的药学上可接受的盐,以及用于治疗眼科疾病,包括白内障和老视症的鲎
甾醇及其衍
生物和25-羟基
胆固醇及其衍
生物的治疗方法和制药组合物和制剂。